Metformin is a popular antidiabetic agent that is also used to treat heart failure patients with type 2 diabetes mellitus. Several reports suggest that metformin may also have cardioprotective effects in patients without diabetes mellitus. In the present study, we investigated the possible therapeutic effect of metformin in heart failure and its underlying molecular mechanisms using a δ-sarcoglycan-deficient mouse model of dilated cardiomyopathy.
D
ilated cardiomyopathy (DCM) is a progressive disease of the heart muscle, which is characterized by left ventricular (LV) dilatation and systolic dysfunction. DCM often results in heart failure and causes potentially life-threatening events that include ventricular arrhythmias, atrioventricular block and syncope, as well as sudden death. 1 The precise cause of DCM is still unknown, as it is associated with a heterogeneous array of conditions that include myocarditis; drug toxicity; chronic incessant tachyarrhythmia; endocrinopathies; nutritional deficiencies; ischemia; metabolic, mitochondrial and genetic abnormalities, and ailments such as hypertension and valvular disease. 1 That said, genetic mutation is known to underlie a significant proportion of DCM. 2 Mutation of the δ-sarcoglycan gene, which encodes a member of a subcomplex of transmembrane proteins within the DGC (dystrophin-glycoprotein complex), has been reported in both familial and sporadic DCM. 3 Despite recent development of an animal model of δ-sarcoglycan deficiency, the pathogenesis of DCM involving the dystrophin-glycoprotein complex remains unclear. And because there is currently no effective cure for DCM caused by δ-sarcoglycan deficiency, current clinical management concentrates on symptomatic treatment of the cardiac and respiratory symptoms. 4 Metformin is a popular antidiabetic agent with an insulin-sensitizing effect. In large-scale clinical trials, metformin therapy decreased the risk of cardiovascular death and the incidence of myocardial infarction associated with diabetes mellitus. [5] [6] [7] In experimental models, metformin was also shown to reduce the severity of heart failure in dogs subjected to rapid ventricular pacing, 8 preserve LV function and survival in mice with permanent left coronary occlusion or occlusion-reperfusion, 9 and improve cardiac remodeling in a long-term postmyocardial infarction mouse model. 10 With regard to Duchenne muscular dystrophy, which shows pathology similar to δ-sarcoglycan deficiency, metformin increased expression of peroxisome PGC (proliferatoractivated receptor γ coactivator)-1 α and utrophin A, 2 potentially useful therapeutic targets, in the skeletal muscle of dystrophin-deficient mdx mice. 11 Although its precise mechanism is not fully understood, these studies suggest that the cardioprotective effects of metformin are mediated via AMPK (AMP-activated protein kinase), an enzyme that is activated in response to changes in cellular energy metabolism and plays a pivotal role in the maintenance of intracellular energy status. Importantly, AMPK is also a key regulator of autophagy, 12 a major system for physiological self-degradation via the lysosomal digestive pathway that is essential for survival, differentiation, development, and homeostasis. 13 Autophagy is also involved the pathogenesis of various diseases. For example, autophagic activation occurs in several heart diseases, including heart failure, cardiac hypertrophy, and ischemic cardiomyopathy. [14] [15] [16] We previously reported that autophagy plays a protective role in myocardial infarction and diabetic cardiomyopathy. 17, 18 In those studies, stimulating autophagy reversed postinfarction remodeling and ameliorated cardiac dysfunction. This suggests enhancing autophagy may mitigate δ-sarcoglycan deficiency-associated DCM. To test that idea, in the present study, we evaluated the effects of metformin on δ-sarcoglycan deficiency-induced DCM and investigated the underlying mechanism, including the role of autophagy.
METHODS
The authors declare that all methods and supporting data are available within the article and its in the Data Supplement. This study conforms to the Guide for the Care and Use of Laboratory Animals published by US National Institutes of Health (NIH publication, 8th Edition, 2011) and was approved by the institutional animal research committee of Gifu University. Mice were housed in a humidity-and temperaturecontrolled environment with 12-hour light/dark cycles and received food and water ad libitum.
Animal Model and Experimental Protocol
δ-Sarcoglycan-deficient (Sgcd −/− ) mice (B6.129-Sgcdtm1Mcn/J) were purchased from Jackson Laboratory (Bar Harbor, ME) and bred as previously described. 19 Sgcd −/− mice develop cardiomyopathy as well as progressive skeletal muscle dystrophy, which is seen morphologically as extensive areas of necrosis/fibrosis within the heart. 20 At 32 weeks of age, Sgcd -/-male mice were assigned to a saline or metformin group (n=10 each) after echocardiographic examination. Metformin (Sigma-Aldrich, St Louis, MO, 200 mg/kg
WHAT IS NEW?
• δ-sarcoglycanopathy is a lethal degenerative muscle disease causing intractable dilated cardiomyopathy.
• Metformin has an insulin-sensitizing effect and has been used to treat diabetes mellitus. In addition to lowering blood glucose levels, metformin exerts pleiotropic effects involving AMP-activated protein kinase in cardiovascular disease.
• Here, we demonstrate that metformin dramatically improves cardiac function and remodeling, and suppresses skeletal muscle degeneration in δ-sarcoglycan-deficient (Scgd −/− ) mice. • These effects are accompanied by enhanced autophagy and ATP production in Scgd −/− hearts.
WHAT ARE THE CLINICAL IMPLICATIONS?
• These findings suggest metformin is a promising and novel therapeutic agent for treatment of sarcoglycanopathy-related dilated cardiomyopathy.
per day) or saline was then administered for 28 days using subcutaneously embedded osmotic mini-pumps (ALZET; DURECT, Cupertino, CA). Mini-pump implant operations were performed under combination anesthesia with halothane (induction, 2%; maintenance, 0.5 %) in a mixture of N 2 O and O 2 (0.5 L/min each) via a nasal mask. Age-matched nontransgenic mice (C57BL/6J, CLEA Japan) served as controls and were administered saline or metformin (n=10 each) as described above. All mice were examined 4 weeks after starting treatment.
Physiological Studies
Echocardiography and cardiac catheterization were performed as described previously using an echocardiographic system (Vevo 770; Visualsonics, Toronto, Canada) equipped with a 45-MHz imaging transducer. 17, 18 Recordings were made before and after the 4-week treatment although the mice were under the combination anesthesia. Just before sacrifice, the right carotid artery was cannulated with a micromanometer-tipped catheter (FTH-1611B-0018; Transonic Science Inc, London, Ontario, Canada) that was advanced through the aorta into the left ventricle to record pressure and maximal and minimal dP/dt (±dP/dt). Cardiac catheterization and blood sampling were performed with mice under the combination anesthesia before they were euthanized by exsanguination.
Blood Chemistry
Blood glucose levels were measured through a tail nick using a glucometer (GR-102, Terumo, Tokyo, Japan). Plasma insulin and HbA1c were each measured using blood collected from the carotid artery after catheterization. Serum insulin levels were assessed using a commercially available mouse insulin ELISA kit (AKRIN-011T, Shibayagi, Gunma, Japan). HbA1c levels were measured by a clinical laboratory (SRL, Tokyo, Japan).
Glucose Tolerance Tests
After an overnight fast (16 hours), 32-week-old male Sgcd −/− mice, age matched wild-type mice, and 8-week old control wild-type mice were intraperitoneally injected with glucose at 1.0 g/kg body weight. Blood glucose levels were then measured through tail nicks using a glucometer (GR-102) 0, 30, 60, 90, and 120 minutes after glucose injection.
Histological Analysis
Once the physiological measurements were complete, mice were euthanized, and their hearts were removed, weighed, and cut into 2 transverse slices through the middle of the ventricles, between the atrioventricular groove and apex. The specimens derived from the basal portion of the hearts were fixed in 10% buffered formalin, embedded in paraffin, cut into 4-μm-thick sections, and stained with hematoxylin-eosin, Masson trichrome, or Sirius red F3BA (0.1% solution in saturated aqueous picric acid; Sigma-Aldrich). Quantitative assessments and morphometric analyses were performed in randomly chosen high-power fields (×400) in each section, as described previously using a multipurpose color image processor (Win ROOF; Mitani Corporation, Tokyo, Japan).
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Immunohistochemistry and Immunofluorescence
After deparaffinization, the previously prepared 4 μm thick sections were incubated with a primary antibody against microtubule-associated protein-1 light chain 3 (LC3; MBL International, Nagoya, Japan), dystrophin (Abcam, Cambridge, MA), or cathepsin D (Santa Cruz Biotechnology, Santa Cruz, CA). A Vectastain Elite ABC system (Vector Laboratories, Burlingame, CA) was then used for immunostaining of dystrophin or cathepsin D, with diaminobenzidine serving as the chromogen. Nuclei were counterstained with hematoxylin. For immunofluorescence, sections were incubated with anti-laminin (Abcam) followed by Alexa Fluor 488 (green; Molecular Probes, Thermo Fisher Scientific K.K., Japan), then counterstained with Hoechst 3342 (Setareh Biotech). They were visualized at 200× with a fluorescent microscope, and images were acquired and quantified using a multipurpose color image processor (Win Roof; Mitani Corporation, Tokyo, Japan). To observe autophagic activity in cardiomyocytes, sections immunostained with anti-LC3 followed by Alexa Fluor 488 were also labeled with antimyoglobin antibody (DAKO, Japan) followed by Alexa Fluor 568 (red; Molecular Probes). These sections were then counterstained with Hoechst 3342 and observed under a confocal microscope (C2; Nikon, Tokyo, Japan). Quantitative assessments, including numbers of immunopositive dots within cardiomyocytes, were performed with 20 randomly chosen high-power fields (×600) using a multipurpose color image processor (BZ-Analyzer; KEYENCE, Osaka, Japan).
Electron Microscopy
Cardiac tissue was quickly cut into 1 mm cubes, immersionfixed in 2.5% glutaraldehyde in 0.1 mol/L phosphate buffer (pH 7.4) overnight at 4°C, and postfixed in 1% buffered osmium tetroxide. The specimens were then dehydrated through a graded ethanol series and embedded in epoxyresin. Ultrathin sections (80 nm), double-stained with uranyl acetate and lead citrate, were examined under a transmission electron microscope (H-800; Hitachi, Tokyo, Japan).
Western Blotting Analysis
Cardiac tissue was homogenized in ice-cold buffer containing 20 mmol/L HEPES (pH 7.4 at 4°C), 25 mmol/L sucrose, 2 mmol/L EGTA, 10 mmol/L potassium chloride, 2 mmol/L magnesium chloride hexahydrate, 5% TritonX-100, 1 mmol/L phenylmethylsulfonyl fluoride, 10 μg/mL leupeptin, 1 mmol/L sodium orthovanadate, 25 mmol/L sodium fluoride, and 50 mmol/L β-glycerophosphate. Homogenates were centrifuged at 1000×g for 5 minutes at 4°C. The supernatant was then collected and the protein quantified using a Bio-RAD Protein Assay (Bio-Rad, CA). Proteins samples (50 μg) were subjected to 7.5%, 10%, or 15% polyacrylamide gel electrophoresis and then transferred onto polyvinylidene difluoride membranes. The membranes were then probed using primary antibodies against GATA-4, myosin heavy chain, troponin I, cathepsin D, utrophin (all from Santa Cruz Biotechnology, Santa Cruz, CA), LC3, p62 (both from MBL International, Nagoya, Japan), dystrophin, Bnip3, Parkin, Pink1 (all from Abcam), AMPK, p-AMPK (phosphorylated AMPK), mammalian target of rapamycin (mTOR), and phosphorylated mTOR (p-mTOR; all from cell Signaling Technology, Danvers, MA), after which the blots were visualized using enhanced chemiluminescence (Amersham/ GE Healthcare, Little Chalfont, United Kingdom). α-Tubulin (analyzed using an antibody from Santa Cruz Biotechnology) served as the loading control. The protein content was expressed as a ratio (arbitrary units) relative to the level of the loading control. Activation of AMPK and mTOR was assessed using antibodies against their phosphorylated forms.
Measurement of Myocardial ATP Content
Myocardial ATP content was measured using an ATP bioluminescent assay kit (TA100, TOYO Ink, Tokyo, Japan) according to the manufacturer's instructions.
Autophagic Flux Assay
We investigated autophagic flux in vivo using previously described methods. 18, 21 Thirty-two-week-old Sgcd −/− mice were administered metformin or saline for 14 days and were then euthanized. Four hours before the animals were euthanized, chloroquine (10 mg/kg; Sigma-Aldrich) was injected intraperitoneally to inhibit fusion of lysosomes and autophagosomes. After death, the hearts were immediately harvested, fixed in 10% formalin for preparation of paraffin-embedded sections, and examined for cardiac autophagy under a confocal microscope after immunofluorescent staining.
Assessment of Skeletal Muscles
Detailed methods are provided in the Data Supplement.
Statistical Analysis
All statistical analyses were performed using Graph Pad PRISM version 6.07 statistical software (GraphPad Software, CA). Data are expressed as means±1 SD. All data were tested for normal distribution using the Kolmogorov-Smirnov test. The significance of difference in variances was tested using Bartlett test. When the data normally distributed and difference in variances was not statistically significant, the significance of differences among groups was evaluated using 1-way ANOVA followed by Tukey test or a repeated-measures ANOVA, as appropriate. Otherwise, the difference was evaluated using the Kruskal-Wallis test. Values of P<0.05 were considered significant.
RESULTS
Effect of Metformin on Cardiac Remodeling and Function in Sgcd −/− Mice
All the mice in both groups survived through the 4 weeks of treatment. However, echocardiography and cardiac catheterization revealed an enlarged LV cavity and impaired LV function in 36-week-old Sgcd −/− mice: LV end-diastolic diameter and pressure were increased, although LV ejection fraction, ±dP/dt, and systolic pressure were all reduced as compared with age-matched wild-type mice (Figure 1 ; Table I in the Data Supplement). The observed LV dilatation and dysfunction were both significantly ameliorated in metformin-treated Sgcd −/− mice: LV systolic pressure was preserved, LV end-diastolic pressure was reduced, and LV systolic and diastolic function was improved. In contrast, in wildtype mice, LV geometry and cardiac function was similar, with or without metformin treatment.
Metabolic Parameters
Metabolic defects have been noted in dystrophic, β-sarcoglycan-null mice. 22 In addition, aging-related defects in glucose homeostasis are also well recognized. We, therefore, performed glucose tolerance tests before treatment and in 8-week-old wild-type mice, which served as a young control. Glucose tolerance was similar in Sgcd −/− and age-matched wild-type mice. Both groups of older mice showed lower glucose tolerance than the young wild-type mice (Figure 2A ). Because metformin is an oral antidiabetic agent that may lower the blood glucose levels, we measured the levels of HbA1c, casual blood glucose, and casual insulin. Levels of HbA1c were lower in Sgcd −/− mice than wild-type mice, but there was no statistical difference in casual blood glucose and insulin levels between the 2 groups ( Figure 2B ; Table II in the Data Supplement) . Importantly, these parameters were similar in Sgcd −/− or wild-type mice, with or without metformin treatment.
Morphometric and Histological Findings in the Heart
Sgcd −/− mice were frailer with lower body weights than wild-type mice, most likely because of atrophic skeletal muscular dystrophy. By contrast, heart weights were increased due in large part to LV hypertrophy, as shown by Masson trichrome staining. As a result, heart weight/body weight ratios were higher in Sgcd −/− than wild-type mice ( Figure 3 and Table II in the Data Supplement). Immunohistochemical analysis revealed that sarcolemmal dystrophin levels were decreased in Sgcd −/− hearts, though cardiomyocyte size was increased (Figure 3 and Table II in the Data Supplement). Sirius red staining showed that myocardial fibrosis, including both the interlacing and replacement types, was significantly greater in Sgcd −/− mice than in age-matched wild-type mice. Metformin treatment attenuated the LV hypertrophy, myocardial fibrosis, and cardiomyocyte hypertrophy.
Electron microscopy revealed severe degeneration within cardiomyocytes from Sgcd −/− hearts ( Figure 4 ). This included loss of myofibrils and myofibril disorganization, mitochondrial dropout and deformities, and increased numbers of autophagic vacuoles. Metformin treatment reversed this subcellular degeneration. Under electron microscopy, no cardiomyocyte membrane damage was detected in either untreated or treated Sgcd −/− hearts ( Figure 4E and 4F) . IgM penetra-tion into fibers was similar between the hearts (data not shown). By contrast, in wild-type mice, heart weight, body weight, and findings at the light microscopic and electron microscopic levels were similar, with or without metformin treatment (Figures 3A through 3F and 4B; Table II in the Data Supplement).
Expression of Sarcomeric Proteins and GATA-4
Myocardial expression of myosin heavy chain, troponin I, and GATA-4 was significantly reduced in Sgcd −/− mice, but the expression levels of all 3 were increased by metformin ( Figure 5 ). However, these proteins expression levels were similar between wildtype groups. Because dystrophin-associated protein complexes contribute to muscle membrane stability, 20 we evaluated myocardial expression of laminin, dystrophin, and utrophin. Utrophin is an autosomal homolog of dystrophin and potentially beneficial to skeletal muscle in mdx mice 11, 23 ( Figure I in the Data Supplement). Levels of laminin and dystrophin expression were lower in Sgcd −/− than wild-type mice and were similar, with or without metformin treatment. Myocardial utrophin expression levels were similar among the groups. These findings suggest that the cardioprotective effect of metformin may be related to an intracellular mechanism in cardiomyocytes rather than protection of the membrane from damage.
Effect of Metformin on Autophagy
Double immunofluorescent labeling revealed that the numbers of LC3-positive autophagic vacuoles were significantly greater within cardiomyocytes from Sgcd −/− mice than wild-type mice ( Figure 6A ). Treatment with metformin further increased the numbers of LC3-dots in Sgcd −/− mice but not wild-type mice ( Figure 6A ). Western blotting showed that levels of LC3-II and p62 were higher in Sgcd −/− than wild-type hearts ( Figure 6B ). As the result, the LC3-II/LC3-I ratio, which is indicative of autophagic turnover, 24 was significantly increased and was increased still further by metformin treatment (Figure 6B) . The increased levels of p62, which impair the final step of autophagy, 25 were reduced by metformin in Sgcd −/− hearts ( Figure 6B ). Immunohistochemistry and Western blotting showed that levels of the lysosomal protein cathepsin D were significantly increased in Sgcd −/− hearts, and were further increased by metformin treatment ( Figure 6C ). Because electron microscopic findings suggest mitochondrial autophagy/mitophagy 26 is enhanced in cardiomyocytes from Sgcd −/− mice, we assessed levels of mitophagy in hearts from Sgcd −/− mice ( Figure 7) . We found that expression levels of Parkin, Pink1, and Bnip3, 3 mitophagy-related molecules, were all upregulated in Sgcd −/− hearts and were further upregulated in Sgcd −/− mice treated with metformin. In contrast, expression levels of Tom20, an indicator of mitochondrial content, were similar among all groups. These findings suggest that the beneficial effect of metformin is associated with mitochondrial autophagy/mitophagy rather than mitochondrial biogenesis. To determine whether the observed increase in the numbers of LC3 dots was because of increased autophagosome formation or impairment of their degradation, we performed in vivo autophagy flux assays in Sgcd 
Effect of Metformin on AMPK and mTOR Activity
We observed a significant increase in the level of activated AMPK (p-AMPK/AMPK) in Sgcd −/− hearts, and those A, Intraperitoneal glucose tolerance tests. P 1 =0.0024 and P 4 =0.0048, value of P between the saline-treated 32-wk-old wild-type (WT) group vs the salinetreated 8-wk-old WT group; P 2 =0.0055 and P 5 =0.0351, value of P between the saline-treated 32-wk-old Sgcd −/− group vs the saline-treated 8-wk-old WT group; P 3 =0.9129 and P 6 >0.9999, value of P between the saline-treated 32-wk-old Sgcd −/− group vs the saline-treated 32-wk-old WT group at each time (n=6 for each). B, Casual blood glucose, HbA1c, and casual plasma insulin levels. These data were collected at the end of the experiment (n=10 for each). Met indicates metformin; Sal, saline; and Sgcd −/− , δ-sarcoglycan-deficient. levels were further increased by metformin ( Figure 8A) . Conversely, the level of mTOR activity (p-mTOR/mTOR), a key regulator of autophagy, was reduced in Sgcd −/− hearts and was further reduced by metformin ( Figure 8A ).
Effect of Metformin on Energy Status of Failing Hearts
Direct ATP measurement revealed that the myocardial ATP content was significantly lower in Sgcd −/− than wild-type hearts ( Figure 8B ). Metformin treatment significantly increased myocardial ATP content in Sgcd −/− hearts but similar in wild-type hearts (Figure 8B ).
Morphometric and Histological Findings in Skeletal Muscles
Finally, we investigated the effect of metformin on skeletal muscles using quadriceps and diaphragm muscles (Figures III and IV in the Data Supplement). The muscles from Sgcd −/− mice exhibited extensive degeneration, necrosis, and regeneration as well as abnormal proportions of small and large muscle fibers. Metformin treatment caused a significant decrease in the percentage of fibers showing central nucleation (a key indicator of muscle damage and regeneration) 27, 28 in both the quadriceps and diaphragm as compared to saline-treated Sgcd −/− mice ( Figure III in the Data Supplement). Because Sgcd −/− muscle fibers go through cycles of muscle degeneration and regeneration, a decrease in central nucleation indicates a reduction in degeneration. IgM penetration into fibers (an indicator of structural integrity of the sarcolemma) 28, 29 in both the quadriceps and diaphragm muscles was markedly lower in metformin-treated than saline-treated Sgcd −/− mice. Masson trichrome staining showed that diaphragm fibrosis was significantly more severe in Sgcd −/− mice than in age-matched wild-type mice and that metformin significantly attenuated fibrosis in Sgcd −/− mice. The numbers of LC3-positive autophagic vacuoles were significantly greater within myocytes in both the quadriceps and diaphragm from Sgcd −/− mice than wild-type mice, and treatment with metformin further increased the numbers of LC3-dots in Sgcd 
DISCUSSION
We found that metformin treatment improved cardiac function and remodeling in sarcoglycanopathy-associated DCM, with no major side effects. Our key findings are that (1) δ-sarcoglycan-deficient mice exhibit features of DCM in which autophagy is activated; (2) metformin treatment mitigates the heart failure by attenuating cardiac fibrosis, hypertrophy, and subcellular degeneration; and (3) metformin increases myocardial ATP content by enhancing autophagy via the AMPK-mTOR pathway.
Possible Cardioprotective Mechanism of Metformin in δ-Sarcoglycan Deficient Hearts
Thirty-six-week-old Sgcd −/− mice showed LV dilatation and impaired cardiac function accompanied by cardiomyocyte hypertrophy and degeneration as well as marked cardiac fibrosis (replacement and interstitial types). These phenotypes are consistent with earlier reports. 4, 30 Additionally, we noted disorganized sarcomere structure, myofibril disarray, mitochondrial degeneration, perinuclear mitochondrial loss, and increased numbers of autophagic vacuoles in cardiomyocytes from Sgcd −/− mice. We demonstrated that autophagy is activated in Sgcd −/− hearts, as evidenced by increases in the numbers of autophagosomes, LC3-II and LC3-II/I ratios, and autophagic flux after short-term chloroquine intervention. We also showed accumulation of p62 protein in Sgcd −/− hearts, which suggests inadequate autophagic turnover. All these changes were mitigated by metformin treatment and, importantly, autophagy was further enhanced in those hearts. Protein degradation and clearance of damaged organelles are essen- tial for proper cellular function. Because autophagy is a major intracellular self-lysosomal degradation and recycling process that also serves an adaptive function to protect organisms against diverse pathologies such as neurodegeneration and heart disease, as well as aging, 13 it seems plausible that its enhancement could underlie the observed favorable findings: improved cardiac function and reduced of cardiac fibrosis, cardiomyocyte hypertrophy, and subcellular degeneration.
Effect of Metformin on Myocardial Energy Status Involving Autophagy
Energy recycling is an important function of autophagy. We previously reported that autophagy increases myocardial ATP levels, enabling cardiac performance to be maintained during periods of starvation and cardiomyocytes to survive under ischemic conditions. 31, 32 It also suppresses postinfarction remodeling. 17 The enzyme AMPK is expressed in various tissues, including the heart, 33 where it serves as a general integrator that responds to changes in cellular energy metabolism and is activated by ATP depletion and the concomitant AMP accumulation (increases AMP/ATP ratio). In addition, AMPK mediates activation of autophagy. 12 In the present study, we observed a significant increase in AMPK activation and decrease in ATP in Sgcd −/− hearts. This suggests that hearts from Sgcd −/− mice are energy-deficient with resultant AMPK activation, despite the enhanced autophagy. Recent studies suggest that the pleiotropic effects of metformin are mediated in part through activation of AMPK. 34 In some contexts, AMPK serves as a positive regulator of autophagy through inhibition of the mTOR complex. 35 Indeed, we previously demonstrated resveratrol activates autophagy via the AMPK-mTOR pathway to improve cardiac performance in postinfarction heart failure and diabetic cardiomyopathy. 17, 18 In the present study, metformin treatment led to AMPK activation and, in turn, mTOR inhibition and increased ATP content accompanied by enhanced autophagy in Sgcd −/− hearts. This suggests metformin increases autophagy through activation of the AMPK-mTOR pathway. This idea is broadly consistent with a recent study by Xie et al, 36 who showed that chronic metformin treatment restores cardiac function in association with increased cardiac autophagy in diabetic OVE mice. They also showed that the beneficial effect of metformin was canceled in diabetic cardiac-specific transgenic mice overexpressing a dominant negative α2 subunit of AMPK. However, their study did not demonstrate a conclusive link between increased autophagy and cardiac remodeling. In the present study, we found that myocardial ATP levels paralleled cardiac function, suggesting that myocardial ATP produced through autophagy contributes mainly to cardiac performance.
Possible Mechanisms Other Than Autophagy/Mitophagy Underlying Beneficial Effects of Metformin
We demonstrated that metformin treatment attenuated skeletal muscle degeneration in Sgcd −/− mice, which is consistent with earlier reports in mdx mice. 11 In particular, fibrosis was significantly reduced in the diaphragm. Because fibrosis in a respiratory muscle like the diaphragm must affect respiratory function, effective treatment is necessary to maintain a sufficient supply of oxygen sufficiently in cases of heart failure. Thus, metformin was suggested to attenuate diaphragm degeneration and the severity of cardiomyopathy through enhancement of autophagy or other unknown mechanisms.
In addition, metformin suppresses development of transverse aortic constriction-induced fibrosis as well as collagen synthesis by cardiac fibroblasts through inhibition of the TGF-β1-Smad3 signaling pathway. 37 It also improves mitochondrial function through activation of AMPK and the downstream signaling pathway involving eNOS (endothelial nitric oxide synthase) and PGC-1α in ischemia-induced heart failure. 9 Long-term metformin treatment reduces cardiomyocyte apoptosis, inhibits cardiac remodeling, and prevents the progression of pacing-induced heart failure in dogs, along with AMPK activation and eNOS production. 8 A recent study demonstrated that metformin mitigates transverse aortic constriction-induced LV hypertrophy and heart failure through the mTOR pathway independently of AMPK-α2, which is the dominant isoform in mouse heart. 38 Further investigation involving specific manipulation of autophagy-related genes will be needed to confirm our findings.
CONCLUSIONS
The present study demonstrated that metformin mitigates cardiac dysfunction and remodeling in 
